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Introduction:
Simple essential tremor (ET) is a neurological disorder of unknown etiology (prevalence: 0.4-3.9%), typically affecting upper limbs and, less commonly, the head, jaw, tongue, trunk and lower limbs. Although a syndrome of tremor in posture and movement, cerebellar motor disturbances, cognitive and personality changes, and hearing and olfactory deficits are also associated with ET (Deuschl et al., 2009) . Interest in essential tremor remains high due to its relatively high prevalence, adverse effect upon quality of life (Schmouth et al., 2014) and apparently increasing prevalence in diseases like multiple sclerosis (MS) (~25%) (Fox et al., 2004) . ET treatment includes pharmacotherapy with beta adrenoceptor blockers, anticonvulsants, neuroleptics and antidepressants, although surgical treatments are required in the ~50% of cases that are pharmacoresistant (Chopra et al., 2013) demonstrating a significant unmet clinical need (Koller et al., 1989) .
Excitotoxic climbing fibre hyperactivity has been suggested as one possible cause of ET and can be emulated in laboratory species by harmaline (i.p.), a beta carboline derivative of harmala alkaloids from Peganum harmala (Syrian Rue) seeds. Harmaline produces an 8-16 Hz tremor in mice and rats and, in rats, is associated with Purkinje cell (PC) loss (Handforth, 2012) .
Recent studies have revealed a role for endocannabinoids in tremor disorders (Glass, 2001; Howard et al., 2013; Arjmand et al., 2015) . Cannabinoid (CB) receptors and their endogenous ligands, the endocannabinoids, are abundant in brain areas that manage motor function where they play a neuromodulatory role (Rodriguez de Fonseca et al., 1998) .
Abundant cerebellar, CB type 1 (CB 1 ) receptors expression, particularly on PC inputs from interneurons and excitatory climbing fibres arising from granule cells and PC synapses emphasises the importance of endocannbinoid signaling in the cerebellum where it modulates classical cerebellar neurotransmission via activity-induced inhibition of presynaptic neurotransmitter release through K + channel-mediated inhibition of presynaptic Ca 2+ influx (Daniel et al., 2004) .
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Although specific changes to cannabinergic signaling in motor diseases remains unclear and significant gaps in our understanding of cannabinergic influences on motor pathways remain, patients have claimed therapeutic benefits of medical cannabis in tremorassociated diseases (Clifford, 1983) . Reduced tremor and spasticity in animal models of MS has been reported following treatment with 9 -tetrahydrocannabinol, a psychoactive plant cannabinoid (Koch et al., 2007; Baker et al., 2000) and numerous but unsubstantiated patient claims for benefits of cannabis use in ET have been made (Tudge et al., 2015) .
Interestingly, an extensive literature shows dose-dependent effects of the CB receptor partial agonist,
9
-tetrahydrocannabinol (THC) in this regard (Frederickson et al., 1976; Kujtan et al., 1983; Stanford et al., 1998; Freedland et al., 2002) . Most notably, a systematic review revealed that Δ 9 -THC was probably ineffective for easing MS-related tremors (Koppel et al., 2014) while, conversely, sustained use of Δ 9 -THC-rich extracts reduced tremor and spasticity in MS (Buccellato et al., 2011) . Thus, a confusing literature surrounds cannabinoid effects upon tremor in MS and, to date, no studies have investigated cannabinoid effects in ET, a discrete disorder. Therefore, here we report effects of a CB receptor agonist and CB 1 receptor antagonists on harmaline-induced tremor in rats, using behavioural measures to determine whether endocannabinoid modulation represents a plausible therapeutic strategy for the treatment of ET, in addition to assessing potential risks associated with therapeutic or recreational use of cannabinoid preparations by ET patients.
Methods:
Male Wistar Kyoto rats (40-60g (P24-28) et al., 2015) . Tests were administered sequentially. Pilot studies (n=16) revealed that 30mg kg -1 harmaline induced stable tremor in this population for the duration of the testing period (2.5-3hrs). Previous studies have revealed that harmaline produces tremor at doses of 9-50mg kg -1 in laboratory rodent species (Handforth, 2012).
Behavioural assays:

Tremor scoring
Tremor was rated by two observers blinded to treatment. Intra-and inter-observer reliability were assessed via kappa coefficient (acceptance criterion: >80% et al., 2015) .
Rotarod test
Motor and balance performance were evaluated by accelerating rotarod device (Hugo Sachs, Germany). Prior to placing an animal on the apparatus, rod rotation was set to 10 rpm. At test start, the animal was placed on the rod which was linearly accelerated at 10 rpm/minute to a maximum of 60 rpm. Each animal undertook three trials with a 30 min intertrial rest interval. The duration for which each animal remained in the apparatus was recorded and the mean for all trials per animal calculated (Vaziri et al., 2015) .
Wire grip test
The wire grip test assesses muscle strength and balance (Marks et al., 2009 This article is protected by copyright. All rights reserved.
Gait analysis test
The gait analysis test assesses animal walking patterns and gait kinematics. The hind paws of each animal were marked with a non-toxic ink and the animal allowed to traverse a clear
) lined with white absorbent paper (100 cm × 10 cm) and ending in a darkened cage. The resulting tracks provide the spatial relationship of consecutive footfalls from which animal stride length and width were measured. Animals were habituated to the runway for 3 training runs before testing. Hind paw stride lengths were measured by distance (cm) between the respective paw prints to the successive ipsilateral prints to assess uni-or bi-lateral effects of treatment upon gait. Hind paw stride widths were measured by distance between the centers of the respective paw prints to the corresponding contralateral stride length measurements at a right angle.
Footprints at the beginning and end of each run were not considered in the analysis (Wecker et al., 2013) .
Drugs
The non-selective CB receptor agonist, WIN55, 212-2 (Sigma, USA), and CB 1 receptor selective antagonists, AM251 (Sigma) and rimonabant (Cayman, USA) were first dissolved in dimethylsulfoxide before further dilution in dH 2 O (DMSO; maximum DMSO concentration:
Harmaline hydrochloride dihydrate (Sigma) was dissolved in dH 2 O. Drugs were administered i.p. to a maximum total injection volume of 1 ml.
Experimental design
The present study comprised three discrete experiments. Experiment 1 assessed the effects of harmaline in the behavioural tests described. Here, two groups of animals were employed, one of which received harmaline (30 mg kg In vitro, AM251 exhibits greater affinity for CB 1 receptors (3-10 fold; dependent on assay) and exerts greater inhibition of agonist effects at CB 1 receptors (6-10 fold difference in IC 50 ; dependent on assay and agonist) (Pertwee (2005) . Therefore, AM251 and rimonabant were employed at doses of 1 and 10 mg kg -1 respectively. CB receptor agonists and antagonists employed in the present study were also examined for effects in the tasks 
Statistical analysis
On entry into the study, 192 animals were randomized, using an online tool (http://graphpad.com/quickcalcs/randomize1/; seeded using the time of day) into 16 groups of 12 animals as described. Where animals failed to complete a task and provide valid data, no value was included for analysis. Reasons for task failure included: failure to habituate to handling, failure to habituate to equipment, technical (e.g. equipment) failure or data provided not amenable to robust analysis (e.g. indistinguishable footprints in the gait task).
The number of animals per group per assay that contributed data for quantitative analysis are shown in parentheses in each figure. Group size was determined by sample size calculation to provide statistical power of ≥80% to detect effect sizes consistent with relevant comparators previously described for this animal model (Handforth, 2012) at the 5% level of significance with the intention to establish differences between control and study drug groups.
Experimental data were collected by researchers blinded to drug treatment and analysed by an independent researcher blinded to group identity. Data were unblinded prior to pairwise statistical comparisons (see below) in order to allow specification of the comparator control group. SPSS (IBM, USA), Origin (OriginLab Co., MA, USA) and
GraphPad Prism 6 (GraphPad Software, USA) were used for statistical analysis of data and figure production. Prior to the conduct of comparative statistics, the presence or not of outlier data points pooled by task was assessed using the ROUT method as implemented in This article is protected by copyright. All rights reserved. ) and effects assessed behaviourally as previously described. Here, an overall effect of treatment upon median harmaline-induced tremor (H(3)=12.1, p<0.05; Fig 3A) , median rearing events (H(3)=13.47, p<0.05; Fig 3B) and median grooming events was seen (H(3)=18.01, p<0.05;
This article is protected by copyright. All rights reserved. In the open field test, no overall effects of treatment upon mean total distance moved (F 3, 41 =2.270, p>0.05; Fig 3D) or median mobility duration (H(3)=4.509, p>0.05; Fig 3E) were seen although mean movement speed (F 3, 37 =4.688, p<0.05; Fig 3F) Fig. 5D ) and mobility duration (AM251: p<0.05; rimonabant: p<0.05; Fig. 5E ) but only rimonabant significantly increased movement speed (p<0.05; Fig 5F) .
In the rotarod test, a main effect of treatment upon mean time on the apparatus was seen (F 2, 23 =47.21, p<0.05) that revealed CB 1 receptor antagonist treatment to significantly increase times on the rod when compared to harmaline plus vehicle controls (AM251: p<0.01; rimonabant: p<0.05; Fig. 6A ). In the grip strength test, a similar effect was seen where the main effect of treatment (F 2, 24 =24.04, p<0.05) arose from significant effects of CB 1 receptor antagonism to increase mean grip time (AM251: p<0.05; rimonabant: p<0.05; Fig.   6B ). Finally, in our analysis of gait, a significant effect of treatment was seen upon median stride width (H(2)=14.71, p<0.05; Fig. 6C This article is protected by copyright. All rights reserved.
Discussion
Essential tremor (ET) is the most common movement disorder (Louis et al., 1998), has
unmet clinical need (~50% pharmacoresistance) and is most frequently cerebellar in origin.
The endocannabinoid system plays an important role in cerebellar function and CB 1 receptor expression is at its most abundant in mammalian cerebellum (Miller et al., 2011) . However, while behavioural effects of CB 1 receptor agonism in healthy laboratory species are well established (Little et al., 1988) , CB 1 receptor modulation in ET has never been examined.
Such a study is important and timely since the endocannabinoid system may represent an unexploited target for ET pharmacotherapy. Moreover, recreational cannabis use and cannabinoid medicine use is increasing, raising exposure risk in ET patients. Finally, recreational abuse of synthetic cannabinoids (typically CB 1 receptor agonists) is also increasing, presenting additional risks within the ET patient population (Fox et al., 2004; Gilman et al., 2014; Tudge et al., 2015) . We therefore assessed the effects of CB receptor agonism and CB 1 antagonism in a murine ET model using five conventional behavioural assessments.
In One of the most reported effects of cannabis in a survey of MS patients was tremor relief (Koch et al., 2007) . However, other studies have reported that cannabis does not improve MS-associated tremor (Fox et al., 2004; Koppel et al., 2014) and static ataxia can be reliably induced by CB 1 receptor agonism in dogs and mice (Dewey et al., 1972) . In our second experiment, we examined the consequences of CB receptor activation upon harmaline-induced behavioural deficits in rat. Here, CB receptor agonism largely benzenesulfonate failed to affect dyskinetic symptoms (Cao et al., 2007) . Moreover, the CB receptor partial agonist, nabilone, also alleviated symptoms in the same model (Fox et al., 2002) and in a small clinical pilot (Sieradzan et al., 2001 ) but these results were not replicated in a randomized-controlled clinical trial . Thus, as found in the present study with respect to CB 1 receptor modulation of ET symptoms, other dyskinesias appear either improved or unaffected by CB 1 receptor antagonism but paradoxically alleviated and exacerbated by CB receptor agonism. This contradiction, exemplified by our own results and those describing therapeutic benefits of CB1 receptor agonism in animal models of chronic tremor (Koch et al., 2007; Baker et al., 2000) may suggest that overall effects are determined by the aetiology of the disorder modelled. Thus, in a chronic encephalomyelitis modelling multiple sclerosis (Baker et al., 2000) where widespread demyelination and axon loss occurs, CB receptor agonism can be of use while in acute This article is protected by copyright. All rights reserved.
tremor arising from cerebellar hyperexcitability (e.g. harmaline treatment) to model idiopathic ET, CB 1 receptor antagonism is beneficial.
In conclusion, our results demonstrate that acute CB 1 receptor antagonism improves severe ET symptoms and so demonstrates their therapeutic potential for ET. Rimonabant was previously licensed for weight loss although was withdrawn in 2008 following reports of psychiatric side effects in a trial population where higher doses were employed (Moreira et al., 2009) . However, adverse reactions of this nature do not necessarily preclude the use of a treatment (e.g. suicidal ideation associated with SSRIs) (Ghaziuddin et al., 2014) and so
should not hinder drug development if warranted by unmet clinical. Moreover, rimonabant has since been shown to act as an inverse agonist at CB 1 receptors (Landsman et al., 1997) and so making investigation neutral CB 1 receptor antagonists (e.g. This article is protected by copyright. All rights reserved.
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